Zacks Company Profile for Celularity, Inc. (CELU : NSDQ) |
|
|
|
Company Description |
Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious and degenerative diseases. Celularity Inc., formerly known as GX Acquisition Corp., is based in NEW YORK.
Number of Employees: 225 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $7.46 |
Daily Weekly Monthly
 |
20 Day Moving Average: 486,406 shares |
Shares Outstanding: 137.72 (millions) |
Market Capitalization: $1,027.40 (millions) |
Beta: -0.40 |
52 Week High: $13.40 |
52 Week Low: $3.63 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-37.15% |
-29.22% |
12 Week |
15.30% |
26.75% |
Year To Date |
45.70% |
81.13% |
|
|
|
|
|
Address & Contact Information |
Street Address |
Phone / Fax |
Email Address |
Web URL |
170 PARK AVE - FLORHAM PARK,NJ 07932 USA |
ph: 908-768-2170 fax: - |
None |
http://www.celularity.com |
|
|
|
General Corporate Information |
Officers
Robert J. Hariri - Chief Executive Officer and Chairman
Andrew L. Pecora - President
David C. Beers - Chief Financial Officer
John Sculley - Director
Jay R. Bloom - Director
|
|
Peer Information
Celularity, Inc. (CORR.)
Celularity, Inc. (RSPI)
Celularity, Inc. (CGXP)
Celularity, Inc. (BGEN)
Celularity, Inc. (GTBP)
Celularity, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 151190105
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
|
|
Share - Related Items
Shares Outstanding: 137.72
Most Recent Split Date: (:1)
Beta: -0.40
Market Capitalization: $1,027.40 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $-0.34 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-1.32 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 3.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 08/15/22 |
|
|
|
|